No Data
No Data
Why Light & Wonder, Neuren, Nick Scali, and QBE Shares Are Falling Today
Neuren Pharmaceuticals Says Angelman Syndrome Drug Shows Promise in Trial; Shares Down 6%
Why Are Neuren Pharmaceuticals Shares Crashing 9%?
Neuren Pharmaceuticals Price Target Cut 11% to A$25.00/Share by Bell Potter
3 ASX Shares Poised to Rise 50% by 2025
This ASX 200 Healthcare Share Is Frozen Amid 'Slower Than Expected' Growth
No Data